☆ 4.8 Article

PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy

NATURE MEDICINE (2022)

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Adham S. Bear et al.

Summary: Activating RAS missense mutations are common in human cancers and can be immunologically targeted. By characterizing HLA class I-restricted mKRAS epitopes, the study successfully isolated and transferred mKRAS-specific TCR to CD8(+) T cells, demonstrating cytotoxicity against mKRAS tumor cells from various origins, with lytic activity correlating with peptide-HLA class I complex abundance. Adoptive transfer of mKRAS-TCR engineered CD8(+) T cells led to tumor eradication in a xenograft model, validating mKRAS peptides as epitopes for immune therapies.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal